… agulants (DOACs) are administered concomitantly with diltiazem, a moderate CYP3A4 inhibitor and a weak P-gp inhibitor, particularly in patients at high risk of bleeding (see section 4.5).
Sucrose
As Slozem contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Identical in all 3 labels. Surrounding text shown from Zentiva.
… time through the gastrointestinal tract could lead to incomplete release of contents of the capsule e.g. in chronic conditions with associated diarrhoea such as Crohns disease or ulcerative colitis.
Patients with rare heriditary problems of fructose intolerances, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicines.
… ith preexisting bronchial hyper-reactivity. Cases have also been reported after dose increase. Patients should be monitored for signs and symptoms of respiratory impairment during diltiazem therapy.
This product contains sucrose, therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Caution should be exercised when direct oral anticoagulants (DOACs) are co-administered with diltiazem which is a moderate CYP3A4 and a weak P-gp inhibitor, particularly in patients at high risk of …